Nuvectis Pharma, Inc. NVCT
- NXP200 — Solid Tumors Phase 1
- NXP200 — Glioma Phase 1
BRAF (3 companies · 4 programs)
Companies with an active program directed at BRAF.
Elicio Therapeutics, Inc. ELTX
- ELI-007 Preclinical
Nurix Therapeutics, Inc. NRIX
- pan-mutant BRAF degrader Preclinical